Flat Medical, a leading innovator in precision positioning solutions for needle procedures, has announced significant strategic breakthroughs in the European healthcare market with its flagship product, the EpiFaith® Smart Syringe. On January 13, 2026, the company secured a framework agreement with the NHS Supply Chain Coordination Limited (SCCL) in the United Kingdom, set to commence on July 1, 2026. This agreement marks a pivotal entry into one of the world's most prestigious public healthcare systems, providing access to the extensive NHS hospital network across the UK.

Simultaneously, Flat Medical obtained a landmark clinical order from Assistance Publique – Hôpitaux de Paris (AP-HP), recognized as Europe's largest hospital system. This order represents a critical transition from clinical validation to standardized procurement, poised to catalyze broader adoption throughout the continent. These achievements underscore the growing demand for advanced medical devices that enhance precision, safety, and efficiency in anesthesia and pain management procedures, core areas within hospital operations.

The EpiFaith® Smart Syringe is engineered to improve the accuracy of needle positioning during critical interventions, reducing risks associated with procedural errors. By integrating smart technology, it addresses longstanding challenges in needle-based procedures, such as those in anaesthesia, where millimeter-level precision can significantly impact patient outcomes. Hospital administrators and procurement professionals will find this development particularly relevant, as it aligns with ongoing efforts to upgrade medical equipment inventories amid rising procedural volumes and staffing pressures.

In the UK, Flat Medical collaborated closely with local partner Fannin UK to navigate the rigorous NHS Supply Chain evaluation process. This partnership not only facilitated approval but also positions the product for scalable deployment across NHS facilities, potentially influencing procurement strategies in other European public health systems. The NHS framework serves as a global benchmark, demonstrating the syringe's compliance with stringent safety, efficacy, and cost-effectiveness standards required for public sector adoption.

In France, the collaboration with IDM Medical enabled penetration into the AP-HP network, comprising over 100,000 healthcare professionals and 39 hospitals. This order validates the product's clinical utility in high-volume environments, where optimizing resource utilization is paramount. For healthcare facility managers, the integration of such smart syringes promises streamlined workflows, reduced complication rates, and potential cost savings through fewer repeat procedures and minimized waste.

Dr. Joseph Luo, CEO of Flat Medical, emphasized the dual endorsements from these institutions as proof of the product's ability to meet both expert performance demands and economic imperatives of healthcare systems. "These successes prove that our innovative products simultaneously satisfy the high-performance demands of experts and the economic efficiency requirements of healthcare systems," he stated. This momentum extends beyond Europe, with explosive growth in North America via collaborations with premier teaching hospitals, market harvest in the Middle East including UAE partnerships and orders from Israel and Lebanon, and advancing commercialization in Japan.

From a broader **Healthcare Management** perspective, these developments highlight the importance of strategic partnerships in accelerating medical technology adoption. Hospital leaders must prioritize devices that support digital transformation in procedural care, aligning with EU initiatives for resilient supply chains and innovative procurement. The EpiFaith® Smart Syringe fits neatly into categories like **Anaesthesia**, **Surgical Equipment**, and **Consumables**, offering tangible benefits in infection control through precise dosing and reduced needlestick injuries.

Looking ahead, these wins are expected to drive revenue growth for Flat Medical while benefiting European hospitals through enhanced procedural safety. Procurement teams can leverage the NHS framework's demonstration effect to negotiate similar terms regionally. As Europe grapples with workforce shortages and rising chronic disease burdens, tools like the EpiFaith® represent investments in operational excellence rather than mere costs. Facility managers should evaluate integration into existing inventories, considering training protocols and compatibility with current anaesthesia workflows.

Regulatory alignment is another key factor; the product's approvals reinforce compliance with evolving EU medical device regulations, including those under discussion in the Critical Medicines Act and medical device reforms. This positions adopters ahead of upcoming harmonized standards updates expected in 2026. Clinical leadership will appreciate data-driven insights from smart features, enabling better patient monitoring and outcome tracking.

In summary, Flat Medical's European breakthroughs signal a new era for precision medical devices, empowering hospitals to elevate standards in **Patient Monitoring** and **Emergency Care**. With operations spanning Taiwan, the USA, and the Netherlands, the company is well-placed to support pan-European rollouts, fostering resilience in supply chains for essential anaesthesia tools. Decision-makers are urged to explore these opportunities to future-proof their facilities against procedural demands.